Stromal antigen-presenting cells and use thereof

Details Stromal antigen-presenting cells and use thereof Stromal antigen-presenting cells and use thereof

2006-05-02

2009-06-30

Ouspenski, Ilia (Department: 1644)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C424S093700

Reexamination Certificate

active

07553661

ABSTRACT:
There is provided a stromal antigen-presenting cell capable of antigen presentation in the context of MHC II. When stimulated with IFNγ the stromal cell expresses B7-H1 and/or CD80. These stromal cells can be used to generate an immune response in an animal.

REFERENCES:
patent: 7195758 (2007-03-01), Schultze et al.
Singh et al., Nature Biotechnology, 1999, 17: 1075-1081.
Pittenger et al. Science. “Multilineage Potential of Adult Human Mesenchymal Stem Cells”, Apr. 2, 1999, pp. 143-147.
Deans et al. “Mesenchymal stem cells: Biology and potential clinical uses”, Exp Hematol. Aug. 28, 2000, pp. 875-884.
Yoon et al. “Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction”, Clin Invest. Feb. 2005;115 (2)pp. 326-338.
Pittenger et al. “Mesenchymal stem cells and their potential ac cardiac therapeutics”, Circ Res. Jul. 9, 2004;95(1) pp. 9-20.
Horwitz et al. “Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta . . . ” Proc Natl Acad Sci U S A. Jun. 25, 2002;99(13) pp. 8932-8937.
Wang et al. “Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: Potential therapy for cystic fibrosis”, Proc Natl Acad Sci U S A. Jan. 4, 2005;102(1)pp. 186-191.
Batholomew et al. “Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin In Vivo”, Hum Gene Ther. Aug. 10, 2001;(12)pp. 1527-1541.
Chuah et al. “Long-term persistence of human bone marrow stromal cells transduced with Factor VIII-retroviral vectors and transient production of therapeutic levels . . . ”, Hum Gene Ther. Mar. 20, 2000;11(5)pp. 729-738.
Studeny et al. “Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors”, Cancer Res. Jul. 1, 2002;62(13)pp. 3603-360.
Eliopoulos et al. “Human-compatible collagen matrix for prolonged and reversible systemic delivery of erythropoietin . . . ” Mol Ther. Oct. 2004;10(4)pp. 741-748.
Stagg et al. “Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy”, Hum Gene Ther. Jun. 2004;15(6)pp. 597-608.
Koc et al. “Allogeneic mesenchymal stem infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH)”, Bone Marrow Transplant. Aug. 2002;30(4)pp. 215-222.
Wakitani et al. “Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-Azacytidine”, Muscle Nerve. Dec. 1995;18(12)pp. 1417-1426.
Woodbury et al. “Adult rat and human bone marrow stromal cells differentiate into neurons”, J Neurosci Res. Aug. 15, 2000;61(4)pp. 364-370.
Reyes et al. “Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells”, Blood. Nov. 1, 2001;98(9)pp. 2615-2625.
Leblanc et al. “HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells”, Exp Hematol. Oct. 2003;31(10)pp. 890-896.
Tse et al. “Suppression of allogeneic t-cell proliferation by human marrow stromal cells: implications in transplantation”, Transplantation. Feb. 15, 2003;75(3)pp. 389-397.
Dinicola et al. “Human bone marrow stromal cells supress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli”, Blood. May 15, 2002;99(10)pp. 3838-3843.
Potian et al. “Veto-like activity of mesenchymal stem cells: Functional discrimination between cellular responses to alloantigens and recall antigens”, J Immunol. Oct. 1, 2003;171 (7)pp. 3426-3434.
Gotherstrom et al. “Immunologic properties of human fetal mesenchymal stem cells”, Am J Obstet Gynecol. Jan. 2004;190 (1)pp. 239-245.
Krampera et al. “Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide”, Blood. May 1, 2003;101(9)pp. 3722-3729.
Djouad et al. “Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals”, Blood. Nov. 15, 2003;102(10)pp. 3837-3844.
Aggarwal et al. “Human mesenchymal stem cells modulate allogeneic immune cell responses”, Blood. Feb. 15, 2005;105(4)pp. 1815-1822.
Glennie et al. “Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells”, Blood. Apr. 1, 2005;105(7)pp. 2821-2827.
Beyth et al. “Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness” Blood. Mar. 1, 2005;105(5)pp. 2214-2219.
Jiang et al. “Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells”, Blood. May 15, 2005;105(10)pp. 4120-4126.
Maccario et al. “Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4 T-cell subsets expressing a regulatory/suppressive phenotype”, Haematologica. Apr. 2005;90(4)pp. 516-525.
Lancet “Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells”, May 1, 2004;363 (9419)pp. 1439-1441.
Meisel et al. “Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation”, Blood. Jun. 15, 2004;103(12)pp. 4619-4621.
Le Blanc et al. “Mesenchymal stem cells inhibit the expression of CD25 (Interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes”, Scand J Immunol. Sep. 2004;60(3)pp. 307-315.
Shen et al. “Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules”, J Immunol. Mar. 15, 1997;158(6)pp. 2723-2730.
Reis E Sousa et al. “Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis”, J Exp Med. Sep. 1, 1995;182(3)pp. 841-851.
Ohkuma et al. “Fluorescence probe measurement of the intralysosmal pH in living cells and the perturbation of pH by various agents”, Proc Natl Acad Sci U S A. Jul. 1978;75(7):pp. 3327-3331.
Porgador et al. “Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody”, Immunity. Jun. 1997;6(6)pp. 715-726.
Canaday et al. “T-cell hybridomas from HLA-transgenic mice as tools for analysis of human antigen processing”, J Immunol Methods. Oct. 1, 2003;281(1-2)pp. 129-142.
Nauta, Alma and Fibbe, Willem E.; “Immunomodulatory properties of mesenchymal stromal cells”, Blood, 2007 110:3499-3508 (prepublished online Jul. 30, 2007).
Gieseke, Friederike, et al.; “Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFN{gamma}R1 signaling and IDO expression”. Blood, 2007 110:2197-2200 (prepublished online May 23, 2007).
LeBlanc, K. et al.; “Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex”. 2003. Scandanavian Journal of Immunology, vol. 57, pp. 11-20.
Stagg, John, et al.; “Interferon-{gamma}-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell”. Blood, 2006 107:2570-2577 (prepublished online Nov. 17, 2005).
Chan, Jennifer, et al.; “Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-{gamma}”. Blood. 2006 107:4817-4824 (prepublished online Feb. 21, 2006).

Affiliated with

Also associated with

Rating

Stromal antigen-presenting cells and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stromal antigen-presenting cells and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stromal antigen-presenting cells and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4076407